Inflation Reduction Act – ASP+8 Biosimilars Payment Increase
CMS is implementing a temporary payment increase for qualifying biosimilars under Medicare Part B. This temporary add on payment will encourage physicians to prescribe biosimilars, helping build a competitive biosimilars market leading to sustainable long term savings for patients and the Medicare program. Increasing access to lower-cost biosimilars will lead to long term savings of up to $8.2 billion in taxpayer dollars over the next 10 years.
Download the below statement and external FAQs from CMS to learn more.